SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO ...Middle East

- Results from the BL-B01D1-303 (NCT06118333) phase III trial presented in a late-breaking oral presentation at ESMO represents the first data readout for iza-bren from a registration enabling study in China REDMOND, Wash., Oct. 19, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a...

Hence then, the article about systimmune announces iza bren meets one of the dual primary endpoints in the bl b01d1 303 trial in recurrent or metastatic npc patients with results presented as a late breaking oral presentation at esmo was published today ( Sunday 19/10/2025 - 03:57 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO )

Also on site :

• Trump’s Christmas Eve calls with children asking about Santa’s whereabouts are steeped in partisan politics
• Update: Flood watch affecting 5 Freeway north of LA until early Friday evening caused by persistent downpours
• Ukraine-Russia war latest: Zelensky awaits Putin response to new peace plan while Christmas Eve blast kills 3 in Moscow